On the slight chance that it does end up improving life expectancy of big dogs prone to DCM because it reduces chances of death due to cardiomegaly, would this then be a cardiovascular drug and not a longevity drug? And are the endpoints anything related to cardiac health outcomes (EF/ heart size/others)?
An extension of the logic would be that all cardiac interventions are longevity interventions because heart diseases are the most common cause of death. That seems odd. Were COVID vaccines longevity interventions cz over time the restored the dip in average life span brought about by the pandemic? (This might just be me not understanding the distinctions around what makes a longevity drug in general; is the goal increasing life, increasing quality of life in later decades, or to reduce overall ageing process/wear and tear starting at a young point ie 40s in humans)
Qn: Could you clarify the intended audience and final use case for this research? It would help to choose between technical depth/accessibility/level of supporting info.